Shares of Argenx SE (ARGX) tumbled 12.80% in pre-market trading on Thursday, despite the company reporting better-than-expected first-quarter earnings. The biotechnology firm's stock price reaction highlights investors' concerns over its operating performance, which fell short of analyst projections.
Argenx reported Q1 earnings of $2.58 per diluted share, surpassing the FactSet analyst consensus of $2.41 and marking a significant turnaround from the $1.04 loss per share in the same quarter last year. However, the company's operating income for the quarter ended March 31 came in at $807.4 million, falling short of the $817.6 million expected by analysts surveyed by FactSet.
Adding to investor uncertainty, Argenx maintained its financial guidance for the fiscal year 2025, targeting combined selling, general and administrative (SG&A) and research and development (R&D) expenses of approximately $2.5 billion. The unchanged guidance, coupled with the lower-than-expected operating income, appears to have overshadowed the positive EPS surprise, leading to the sharp pre-market decline in Argenx's stock price.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。